MedTrace Logo

Multicenter Study on Detection Strategy of Infectious Diseases in Blood Transfusion

NCT04471688 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2020-07-15

No results posted yet for this study

Summary

In the past ten years, nucleic acid detection technology has overcome the limitations of serological detection, reduced missed detections due to window period, occult infection, etc., and its application in the field of pathogen detection has developed rapidly. Since 2015, domestic blood collection and supply institutions have fully popularized nucleic acid testing. The safety screening of blood sources mostly adopts the method of combining two times of enzyme-free negative and one time of nucleic acid testing, which excludes the guarantee of blood safety to the greatest extent.

At present, the clinical pre-transfusion and pre-operative infectious disease screening in our country is still serological detection. The use of nucleic acid detection for infectious disease screening can better realize the significance of patients' pre-transfusion/pre-operative infectious disease screening. Therefore, this study will analyze the nucleic acid detection technology and clinical serological detection technology in order to solve three problems:

* Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening; ② Explore the confirmation process of the gray area results of infectious disease serological testing; ③ Better realize the significance of screening for patients' infectious diseases.

Conditions

  • Infectious Disease Screening

Interventions

DIAGNOSTIC_TEST

infectious disease screening

Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening

Sponsors & Collaborators

  • SANSURE BIOTECH INC.

    collaborator UNKNOWN

  • The Third Xiangya Hospital of Central South University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04471688 on ClinicalTrials.gov